Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Statistics
Share Statistics
Denali Therapeutics has 145.22M shares outstanding. The number of shares has increased by 1.83% in one year.
| Shares Outstanding | 145.22M |
| Shares Change (YoY) | 1.83% |
| Shares Change (QoQ) | 0.9% |
| Owned by Institutions (%) | 75.5% |
| Shares Floating | 125.71M |
| Failed to Deliver (FTD) Shares | 1.32K |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 11.44M, so 7.95% of the outstanding shares have been sold short.
| Short Interest | 11.44M |
| Short % of Shares Out | 7.95% |
| Short % of Float | 9.31% |
| Short Ratio (days to cover) | 10.25 |
Valuation Ratios
The PE ratio is -7.93 and the forward PE ratio is -5.77. Denali Therapeutics's PEG ratio is -0.06.
| PE Ratio | -7.93 |
| Forward PE | -5.77 |
| PS Ratio | 0 |
| Forward PS | 2.6 |
| PB Ratio | 2.73 |
| P/FCF Ratio | -9.22 |
| PEG Ratio | -0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Denali Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.46, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.46 |
| Quick Ratio | 8.46 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.09 |
| Debt / FCF | -0.12 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1M |
| Employee Count | 422 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -68K |
| Effective Tax Rate | 0.02% |
Stock Price Statistics
The stock price has increased by 3.68% in the last 52 weeks. The beta is 1.58, so Denali Therapeutics's price volatility has been higher than the market average.
| Beta | 1.58 |
| 52-Week Price Change | 3.68% |
| 50-Day Moving Average | 15.62 |
| 200-Day Moving Average | 22.44 |
| Relative Strength Index (RSI) | 58.89 |
| Average Volume (20 Days) | 1.35M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -487.34M |
| Net Income | -422.77M |
| EBITDA | -487.34M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.57 |
Balance Sheet
The company has 174.96M in cash and 42.29M in debt, giving a net cash position of 132.67M.
| Cash & Cash Equivalents | 174.96M |
| Total Debt | 42.29M |
| Net Cash | 132.67M |
| Retained Earnings | -1.54B |
| Total Assets | 1.37B |
| Working Capital | 762.23M |
Cash Flow
In the last 12 months, operating cash flow was -347.69M and capital expenditures -15.91M, giving a free cash flow of -363.61M.
| Operating Cash Flow | -347.69M |
| Capital Expenditures | -15.91M |
| Free Cash Flow | -363.61M |
| FCF Per Share | -2.21 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DNLI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for DNLI is $33, which is 112.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $33 |
| Price Target Difference | 112.8% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
Scores
| Altman Z-Score | 5.57 |
| Piotroski F-Score | 2 |